Enrolling Patients

You can start the enrollment process for your patients using one of the Taltz contracted specialty pharmacies or through Taltz Together.


If enrolling directly through a specialty pharmacy, first make sure it is included on the list of Taltz contracted specialty pharmacies below. If your specialty pharmacy is included, please visit the pharmacy's website to access its enrollment form and submit it as directed by the pharmacy.



Enroll your patients through Taltz Together by completing the enrollment form below. Taltz Together will connect patients with the appropriate contracted specialty pharmacy. Patients participating in Taltz Together will be able to choose the support services that best suit their individual needs.

Fax the completed enrollment form to 1-844-344-8108.

To access the list of contracted specialty pharmacies in Puerto Rico, please contact your local sales representative.

Taltz Together™ is a trademark of Eli Lilly and Company.


The Taltz Clear Access Program

Assuring access so your patients* can confidently get Taltz.

*For commercially insured patients only.

The Taltz Clear Access Program

Assuring access so your patients* can confidently get Taltz.

*For commercially insured patients only.

Download Savings Cards

Each card has a unique ID number. Please do not make copies.


ERROR: We are currently experiencing technical difficulties. We were unable to submit your information. Please try again at another time. We apologize for the inconvenience.
Thank you for downloading your Taltz Savings Card! Your download has begun. If there is a problem, try downloading again.
Thank you! Your savings card has been emailed to you. If you do not receive it, please check your spam or try emailing it again.


Eligible patients pay as little as $5 a month for their Taltz prescription. Other terms and conditions apply.


per month

Commercially insured patients with Taltz coverage will pay $5 per month with the Taltz Savings Card for up to 24 months.


per month

Commercially insured patients without Taltz coverage will pay $25 per month with the Taltz Savings Card for up to 24 months.

Bridge Program: If your patient’s commercial insurance coverage changes, he or she will be eligible to receive Taltz for $25 per month for up to 24 months.

Eligibility Criteria.

Offer good for up to 24 months. $5 Monthly offer subject to a maximum annual benefit of $16,000. $25 Monthly offer subject to a monthly and annual cap of wholesale acquisition cost plus usual and customary pharmacy charges. Card must be first used by 12/31/2017.


Taltz Together is here to provide the resources and support you and your patients need. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966).

taltz together offerings include:

Injection Training

Injection Training

  • Free of charge to patients and their families
  • Patients can choose either in-person or telephone training
  • Injection training videos available here
1-on-1 Support

1-on-1 Patient Support Specialist

  • A personal patient resource to help answer questions or concerns
  • Help is available Monday-Friday from 8 AM to 10 PM ET
Access Assistance

Access Assistance

Indication and Important Safety Information

Taltz is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Important Safety Information for Taltz (ixekizumab)


Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Warnings and Precautions


Taltz may increase the risk of infection. The Taltz group had a higher rate of infections than the placebo group (27% vs 23%). Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Patients receiving Taltz should be monitored closely for signs and symptoms of active TB during and after treatment.


Serious hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease.


Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Live vaccines should not be given with Taltz.

Adverse Reactions

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Click to access Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.